Patients with higher baseline levels of I-FABP had better clinical outcomes after 6 weeks of SSRI treatment, as measured by the decrease in their depression score on the 24-item Hamilton Depression Rating Scale (dHDRS24) [86]. The gene discussed is FABP2; the disease is depressive symptom measurement.